Gastrointestinal and liver adverse effects of drugs used for treating IBD

Best Practice and Research: Clinical Gastroenterology

Volumn 24, Issue 2, 2010, Pages 157-165

  Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adverse effects; Hepatotoxicity; Inflammatory bowel disease; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZAFALK; AZAREK; AZASAN; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; FOLIC ACID; GLUCOCORTICOID; MERCAPTOPURINE; MESALAZINE; MESAZIN; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAPRED; PLACEBO; PREDNISOLONE; PREDNISOLONE SODIUM SUCCINATE; PREDNISONE; PROGRAL; SALAZOSULFAPYRIDINE; STERAPRED; TACROLIMUS; THIOGUANINE DERIVATIVE; TIOGUANINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGIC DISEASE; ARTHRALGIA; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BLOATING; BONE MARROW SUPPRESSION; CHOLESTASIS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONSTIPATION; CROHN DISEASE; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ENTERITIS; FATIGUE; FATTY LIVER; FEVER; FIBROSIS; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFLAMMATION; INSULIN RESISTANCE; INTESTINE ULCER; KIDNEY DYSFUNCTION; LEUKEMIA; LIVER BIOPSY; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HYPERPLASIA; LIVER NECROSIS; LIVER TOXICITY; LUNG FIBROSIS; NAUSEA; NAUSEA AND VOMITING; OBESITY; PANCREATITIS; PELIOSIS HEPATIS; PEPTIC ULCER; PORTAL HYPERTENSION; PSORIASIS; RASH; RHEUMATIC DISEASE; SIDE EFFECT; SMALL INTESTINE RESECTION; STOMATITIS; THROMBOCYTOPENIA; TREMOR; ULCERATIVE COLITIS; VEIN OCCLUSION; VOMITING;

ANTI-INFLAMMATORY AGENTS; DRUG-INDUCED LIVER INJURY; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER; RISK ASSESSMENT; RISK FACTORS;

EID: 77749343043     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2009.10.011     Document Type: Article

References (54)

1. Schafer-Korting M., Kleuser B., Ahmed M., et al. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol Physiol 18 (2005) 103-114
2. Ross A.S., and Cohen R.D. Medical therapy for ulcerative colitis: the state of the art and beyond. Curr Gastroenterol Rep 6 (2004) 488-495
3. Gold R., Buttgereit F., and Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117 (2001) 1-8
4. Scribano M., and Prantera C. Review article: medical treatment of moderate to severe Crohn's disease. Aliment Pharmacol Ther 17 Suppl. 2 (2003) 23-30
5. Truelove S.C., and Witts L.J. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1 (1959) 387-394
6. Jones F.A. Medical treatment of Crohn's disease of the colon. Bibl Gastroenterol (1970) 143-144
7. Lennard-Jones J.E. Medical aspects of Crohn's disease. Proc R Soc Med 61 (1968) 81-83
8. Jones J.H., and Lennard-Jones J.E. Corticosteroids and corticotrophin in the treatment of Crohn's disease. Gut 7 (1966) 181-187
9. Jewell D.P. Corticosteroids for the management of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 18 (1989) 21-34
10. Malchow H., Ewe K., Brandes J.W., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86 (1984) 249-266
11. Brattsand R., and Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 10 Suppl. 2 (1996) 81-90 discussion 91-92
12. Fiocchi C. Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol Dietol 48 (2002) 215-226
13. de Haij S., Daha M.R., and van Kooten C. Mechanism of steroid action in renal epithelial cells. Kidney Int 65 (2004) 1577-1588
14. Fiocchi C. Inflammatory bowel disease: dogmas and heresies. Dig Liver Dis 34 (2002) 306-311
15. Carson J.L., Strom B.L., Schinnar R., et al. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med 91 (1991) 223-228
16. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 (1991) 735-740
17. Wolfe F., and Hawley D.J. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 27 (2000) 1668-1673
18. Di Fazano C.S., Messica O., Quennesson S., et al. Two new cases of glucocorticoid-induced pancreatitis. Rev Rhum Engl Ed 66 (1999) 235
19. Sandborn W.J. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 225 (1998) 92-99
20. Lees C.W., Maan A.K., Hansoti B., et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 27 (2008) 220-227
21. de Boer N.K., Mulder C.J., and van Bodegraven A.A. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med 63 (2005) 444-446
22. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
23. Fraser A.G., Orchard T.R., and Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50 (2002) 485-489
24. Schwab M., Schaffeler E., Marx C., et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12 (2002) 429-436
25. Reshamwala P.A., Kleiner D.E., and Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 44 (2006) 7-14
26. Dubinsky M.C., Vasiliauskas E.A., Singh H., et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125 (2003) 298-303
27. Vernier-Massouille G., Cosnes J., Lemann M., et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 56 (2007) 1404-1409
28. Geller S.A., Dubinsky M.C., Poordad F.F., et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 28 (2004) 1204-1211
29. Seiderer J., Zech C.J., Reinisch W., et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 43 (2005) 303-309
30. de Boer N.K., van Bodegraven A.A., Jharap B., et al. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 686-694
31. Derijks L.J., Gilissen L.P., de Boer N.K., et al. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?. J Hepatol 44 (2006) 821-822
32. Gilissen L.P., Derijks L.J., Driessen A., et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?. Dig Liver Dis 39 (2007) 156-159
33. Feagan B.G., and Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 33 (2004) 407-420
34. Feagan B.G., Rochon J., Fedorak R.N., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332 (1995) 292-297
35. Themido R., Loureiro M., Pecegueiro M., et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 72 (1992) 361-364
36. Boffa M.J., Chalmers R.J., Haboubi N.Y., et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 133 (1995) 774-778
37. Whiting-O'Keefe Q.E., Fye K.H., and Sack K.D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90 (1991) 711-716
38. Roenigk Jr. H.H., Auerbach R., Maibach H., et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38 (1998) 478-485
39. Ortiz Z., Shea B., Suarez Almazor M., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev (2000) CD000951
40. Fathi N.H., Mitros F., Hoffman J., et al. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 29 (2002) 2092-2098
41. Schwartz M., and Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 10 (2008) 585-590
42. Van Assche G., Vermeire S., and Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol 14 (2008) 5508-5511
43. Garcia-Lopez S., Gomollon-Garcia F., and Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 28 (2005) 607-614
44. Shibolet O., Regushevskaya E., Brezis M., et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev (2005) CD004277
45. Hare N.C., Arnott I.D., and Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2 (2008) 357-370
46. Baumgart D.C., Macdonald J.K., and Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev (2008) CD007216
47. Yamamoto S., Nakase H., Mikami S., et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 28 (2008) 589-597
48. Benson A., Barrett T., Sparberg M., et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 14 (2008) 7-12
49. Ullman T.A. Tacrolimus for active ulcerative colitis? Yes! (Even though Cochrane says "no"). Gastroenterology 132 (2007) 1192-1194
50. Ogata H., Matsui T., Nakamura M., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55 (2006) 1255-1262
51. Klintmalm G.B. Clinical use of FK 506 in liver transplantation. Transplant Proc 28 (1996) 974-976
52. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 23 (2004) S202-S206
53. Chow D.K., and Leong R.W. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 6 (2007) 479-485
54. Baumgart D.C., Pintoffl J.P., Sturm A., et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol 101 (2006) 1048-1056